Home > Boards > US Listed > Biotechs >

Jounce Therapeutics Inc. (JNCE)

Add JNCE Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/30/2017 2:24:53 AM - Followers: 3 - Board type: Free - Posts Today: 0

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
JNCE News: Current Report Filing (8-k) 01/07/2019 08:06:29 AM
JNCE News: Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014 01/03/2019 08:00:00 AM
JNCE News: Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference 01/02/2019 08:00:00 AM
JNCE News: Amended Statement of Ownership (sc 13g/a) 12/10/2018 09:04:35 AM
JNCE News: Quarterly Report (10-q) 11/13/2018 11:07:24 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#2   Partner Fund Management, L.P. has filed a new wiltonio 09/30/17 02:24:52 AM
#1   JNCE bullish 24.61 stocktrademan 05/11/17 01:49:16 PM